AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 222 min read$SER

Venkatesan Jay purchased $1K of SER

Venkatesan Jay purchased 589 shares of Serina Therapeutics, Inc. (SER) at $1.78 on 2026-05-22.

Original reporting
SEC EDGAR · Venkatesan Jay
Published Jun 22, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 11:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SER
Bullish
medium confidence
Mentioned
$SER
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (589 shares at $1.7800; total $1,048.42) filed on 2026-06-22.

02

Market read

Traders may note the insider buy, but the disclosed dollar value is too small to be a standalone catalyst.

03

What to watch

No 10b5-1 plan and no follow-on pattern (only one transaction) limits inference about sustained insider conviction.

Relevance 4/10Novelty 2/10Timing: after-hours/filing timestamp (2026-06-22) for an SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction filing for Serina Therapeutics, Inc.

Company-level read

Ticker impact

$SERBullishMedium confidence
Context

Serina Therapeutics disclosed via SEC Form 4 that director Venkatesan Jay bought 589 shares at $1.7800 on 2026-05-22.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider buys can be read as confidence, but the disclosed size (~$1.0k) and lack of 10b5-1 plan detail make it low material for trading decisions.

Market effects

Sector

No sector read-through; this is a company-specific, small insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The purchase is very small and may reflect personal liquidity/compensation rather than a strong forward-looking signal.

Key entities

  • issuer
    Serina Therapeutics, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • insider
    Venkatesan Jay

    Director who reported the open-market purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SER insider trading history →

Related articles

AUG 13
$SERMed

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics, Inc. (SER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates – Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - – Top-line data from the single-ascending-dose arm targeted for the first half

SEC EDGAR 8-K4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min